#76
|
|||
|
|||
Ñïàñèáî. Îäîáðÿëêà íå ðàáîòàò.
Òóò ëîãèêà ñëåäóþùàÿ: Ïðîãðåññèþ çàáîëåâàíèÿ íàäî â ëþáîì ñëó÷àå êîíòðîëèðîâàòü (àêðàëüíàÿ êîìïåíñàöèÿ, íîâûå ñòåíîçû è îêêëþçèè). Íå ïðîïóñòèòü ïîêàçàíèå ê ðåâàñêóëÿðèçàöèè (îñîáåííî â ñèòóàöèÿõ ñ ïîãðàíè÷íîé àêðàëüíîé êîìïåíñàöèåé è âûñîêèì ðèñêîì ðåâàñêóëÿðèçàöèè ó òÿæåëûõ ïàöèåíòîâ), êîíòðîëè ïîñëå èíòåðâåíöèé èëè îïåðàòèâíûõ âìåøàòåëüñòâ (íàïðèìåð, åñëè ôîðìèðóåòñÿ ðåñòåíîç, òî êàêîå-òî âðåìÿ îí ìîæåò áûòü áåññèìïòîìíûì, à ïîòîì, îêêëþçèÿ è, åñëè íå ïîâåçëî, ðåâàñêóëÿðèçàöèÿ âìåñòî ìàëî èíâàçèâíîé PTA óæå òîëüêî õèðóðãè÷åñêèìè ìåòîäàìè) è ò.ä. À òåïåðü ðàññìîòðèì äâà ñöåíàðèÿ: 1. Âðà÷, êîíòðîëèðóþùèé ïðîãðåññèþ çàáîëåâàíèÿ, îòäåëüíî íàçíà÷àåò ïðè êàæäîì êîíòðîëå ïîñåùåíèå òåðàïåâòà (à âäðóã Âàì íàäî äîçó "ïðèëà" ïîäïðàâèòü? à âäðóã íå íàäî?). Òåðàïåâò îò òàêèõ ÷àñòûõ êîíòðîëåé îçâåðååò è íå ïîéìåò (â áîëüøèíñòâå ñëó÷àåâ ñ äîçèðîâêîé âñå íîðìàëüíî) 2. Âðà÷, êîíòðîëèðóþùèé ïðîãðåññèþ çàáîëåâàíèÿ, îäíîâðåìåííî èìååò õîðîøóþ òåðàïåâòè÷åñêóþ ïîäãîòîâêó. Îí/îíà òðàòèò íåñêîëüêî äîïîëíèòåëüíûõ ìèíóò ïðîñìàòðèâàåò ëèñò ëåêàðñòâ è àíàëèçîâ è óáåæäàåòñÿ ïðè êàæäîì àíãèîëîãè÷åñêîì êîíòðîëå â òîì, ÷òî ìåäèêàìåíòîçíàÿ òåðàïèÿ âåäåòñÿ àäåêâàòíî. Êàêàé èç äâóõ ñèñòåì áóäåò áîëåå ýôôåêòèâíàÿ? |
#77
|
|||
|
|||
«Áîëüøèíñòâî ïðè÷èí çàáîëåâàíèé ñåðäöà íàì èçâåñòíû. Êëþ÷åâàÿ ïðîáëåìà íàñòîÿùåãî âðåìåíè - ïðèìåíåíèå òîãî, ÷òî ìû çíàåì, äëÿ ïðåäóïðåæäåíèÿ ïðåæäåâðåìåííûõ áîëåçíåé ñåðäöà».
S.Yusuf Ñòàòèíû, àñïèðèí è èÀÏÔ â øèðîêèå òåðàïåâòè÷åñêèå ìàññû! |
#78
|
||||
|
||||
Óâàæàåìûé êîëëåãà!
Íó, ïðàâî, ïåðå÷èòàéòå ñâîè èñõîäíûå ïîñòû. Èç íèõ ìîæíî ñäåëàòü âûâîä, ÷òî PAD îïàñíåå CAD. Ïðè ýòîì Âû äåéñòâèòåëüíî íå ãîâîðèëè î òîì, èäåò ðå÷ü îá èçîëèðîâàííîì ïîðàæåíèè èëè íåò, õîòÿ ýòî ïðèíöèïèàëüíî è ñëåäîâàëî îãîâîðèòü ñðàçó. Ïðî òî, ÷òî ãðàæäàíå ñ PAD ÷àñòî èìåþò àòåðîñêëåðîç íåñêîëüêèõ áàññåéíîâ èçâåñòíî áûëî è äî àâòîðîâ äàííîãî ðåãèñòðà äàæå íà îñíîâàíèè ïðîñòûõ êëèíè÷åñêèõ íàáëþäåíèé. Ðåãèñòð ëèøü ïîäòâåðäèë èõ. Ïî òåìå, ñòîëü Âàñ âîëíóþùåé. Ïðîùå íàó÷èòü âðà÷à, êîíòðîëèðóþùåãî íîãè ëå÷åíèþ ãèïåðòîíèè è äèñëèïèäåìèè - íå âåëèêà íàóêà. Íàçíà÷åíèå àñïèðèíà âîîáùå íå îáñóæäàåòñÿ. |
#79
|
|||
|
|||
Öèòàòà:
Öèòàòà:
2. Ðàçâå ðàáîòà íå äîêàçàëà, ÷òî ñìåðòíîñòü ó ïàöèåíòîâ ñ PAD âûøå, ÷åì ó ïàöèåíòîâ ñ CAD? "èçâåñòíî áûëî è äî àâòîðîâ äàííîãî ðåãèñòðà äàæå íà îñíîâàíèè ïðîñòûõ êëèíè÷åñêèõ íàáëþäåíèé" - â âåê EBM ýòî íåñåðüåçíî. Òåïåðü ïî "âîëíóþùåìó ìåíÿ âîïðîñó" : Âû ïèøåòå: Öèòàòà:
Âîò è ïîëó÷àåòñÿ, ÷òî ïàöèåíòû ñ PAD äîëæíû êîíòðîëèðîâàòüñÿ òåðàïåâòàìè, âëàäåþùèìè "êîíòðîëåì íîã" è "ëå÷àùèìè ãèïåðòîíèþ è äèñëèïèäåìèþ". Ìîæåò, òàêèõ âðà÷åé íàçâàòü íå àíãèîëîãàìè, à êàê-íèáóäü ïî-äðóãîìó? Èëè âîîáùå íèêàê íå íàçâàòü? Ñ ìîåé òî÷êè çðåíèÿ, ýòî íåïðèíöèïèàëüíî. |
#80
|
|||
|
|||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Èòàê ïåðâûé âîïðîñ - äåéñòâèòåëüíî ëè íàëè÷èå PAD ãîâîðèò î õóäøåì ïðîãíîçå? Ïåðâîå, ÷òî íàäî îïðåäåëèòü - êàêîâî êîëè÷åñòâî ïàöèåíòîâ ñ èçîëèðîâàííûìè ïîðàæåíèÿìè â ðååñòðå. Îêàçûâàåòñÿ, ÷òî ïàöèåíòîâ ñ èçîëèðîâàííîé PAD 3246, ÷òî â 3 ðàçà ìåíüøå, ÷åì ïàöèåíòîâ ñ èçîëèðîâàííîé CVD (10603) è â 9 ðàç ìåíüøå, ÷åì ñ èçîëèðîâàííîé CAD (28867). Òî åñòü òàêèõ ïàöèåíòîâ âîîáùå ìåíüøå, à äîâåðèòåëüíûå èíòåðâàëû äëÿ ýòîé ïîäãðóïïû áóäóò çàêîíîìåðíî øèðå. È ÷òî ìû âèäèì â öèôðàõ èñõîäîâ - ó ïàöèåíòîâ ñ èçîëèðîâàííîé PAD íåò ðàçëè÷èé â íåôàòàëüíûõ ÈÌ, îæèäàåìî íèæå, ÷åì ó ïàöèåíòîâ ñ CVD íåôàòàëüíûé èíñóëüò è íèæå , ÷åì ó ïàöèåíòîâ ñ CVD ðèñê ïî êîìïîçèòíîé òî÷êå êàðäèîâàñêóëÿðíîé ñìåðòè, ÈÌ è èíñóëüòà. Åñëè ê ýòîé êîìïîçèòíîé òî÷êå äîáàâëÿåòñÿ ãîñïèòàëèçàöèÿ - òî â ãðóïïå èçîëèðîâàííîé PAD ðèñê çíà÷èìî âûøå, ÷åì â äðóãèõ èçîëèðîâàííûõ ãðóïïàõ. Çíà÷èò, ïàöèåíòû ñ èçîëèðîâàííîé PAD çíà÷èìî ÷àùå ãîñïèòàëèçèðóþòñÿ. Ãîâîðèò ëè ýòî î õóäøåì ïðîãíîçå? Òåïåðü ïîñìîòðèì íà ìóëüòèñîñóäèñòîå ïîðàæåíèå. Åñëè ê PAD äîáàâëÿåòñÿ CAD, òî çíà÷èìî âîçðàñòàåò (â ñðàâíåíèè ñ èçîëèðîâàííîé PAD) ðèñê îáùåé ñìåðòíîñòè, êàðäèîâàñêóëÿðíîé ñìåðòíîñòè, êîìïîçèòíîé òî÷êè êàðäèîâàñêóëÿðíîé ñìåðòè, ÈÌ è èíñóëüòà. Ïðàêòè÷åñêè òî æå ñàìîå íàáëþäàåòñÿ äëÿ ãðóïïû CAD+CVD, äà åùå âûøå ó íèõ ðèñê íåôàòàëüíîãî èíñóëüòà. È òîëüêî â êîìïîçèòíîé òî÷êå ñ ãîñïèòàëèçàöèåé â ãðóïïå CAD+PAD ðèñê âûøå. Òî åñòü, ðèñê ôàòàëüíîñòè îïðåäåëÿåòñÿ íå íàëè÷èåì PAD, à ìíîãîñîñóäèñòûì ïîðàæåíèåì, à ïàöèåíòû ñ PAD çíà÷èìî ÷àùå ãîñïèòàëèçèðóþòñÿ. Ãäå æå õóäøèé ïðîãíîç äëÿ êàòåãîðèè PAD? In an analysis of event rates as a function of the number of symptomatic arterial beds affected, counting patients with multiple risk factors only as 0 symptomatic beds, event rates increased in stepwise fashion with the number of symptomatic vascular beds, with the end point of CV death, MI, stroke, or hospitalization for a CV event ranging from 5.31% of patients with risk factors only to 12.58% with 1, 21.14% with 2, and 26.27% with 3 disease locations (P<.001 for trend). [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] Òåïåðü âòîðîé âîïðîñ - ñðåäè ïàöèåíòîâ ñ PAD ñîïóòñòâóþùèå ïîðàæåíèÿ äðóãèõ áàññåéíîâ âñòðå÷àþòñÿ ãîðàçäî ÷àùå. Äàâàéòå äëÿ íàãëÿäíîñòè îáðàòèìñÿ ê äðóãîé ïóáëèêàöèè ðååñòðà, êîòîðàÿ ñêîðî ïîÿâèòñÿ â European Heart Journal [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ], è îïèñûâàåò óæå 3-õ ëåòíèå èñõîäû. Type and distribution of monovascular and polyvascular disease at baseline in patients eligible for 3-year follow-up. Data labels report the number of patients with each disease type. [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] ×àùå ëè ïðè PAD íàáëþäàþòñÿ ñîïóòñòâóþùèå ïîðàæåíèÿ äðóãèõ áàññåéíîâ? Òðåòèé âîïðîñ - ñìåðòíîñòü ó ïàöèåíòîâ ñ PAD âûøå, ÷åì ó ïàöèåíòîâ ñ CAD. ×àñòè÷íî, ýòî ðàññìîòðåíî â ïåðâîì âîïðîñå ãäå âèäíî, ÷òî èçîëèðîâàííàÿ PAD íå ïîâûøàåò ðèñê ñìåðòíîñòè, â ñðàâíåíèè ñ èçîëèðîâàííîé CAD, à ïðè êîìáèíèðîâàííîé PAD ðèñêè îïðåäåëÿþòñÿ, â îñíîâíîì, ÷èñëîì ñîñóäèñòûì ïîðàæåíèé. Èçìåíèëîñü ëè ÷òî-ëèáî ÷åðåç 3 ãîäà?  ïóáëèêàöèè àâòîðû "ïîñêóïèëèñü" íà äîâåðèòåëüíûå èíòåðâàëû, ïîýòîìó ñëîæíî îöåíèâàòü çíà÷èìîñòü ðàçëè÷èé. Íà ïåðâûé âçãëÿä, âðîäå áû òåçà Ðîìàíà ïîäòâåðæäàåòñÿ: [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] Event rates per 100 patient-years at 3 years for important vascular outcomes by the type of symptomatic disease present at study entry. Coronary artery disease, cerebrovascular disease, and peripheral arterial disease groups include patients with single bed as well as polyvascular disease. Îäíàêî æ Over the 3-year course of REACH, patients with PAD only at baseline had the highest risk of progressing to involvement of other vascular beds, which may explain some of the high event rates seen among this population. Almost 10% of the PAD patients progressed to polyvascular disease over 3 years, compared with 4% of patients with either CAD or CVD at baseline. The most common progression on a percentage basis was patients with PAD to develop CAD (6.1%), followed by patients with PAD to develop CVD (3.8%), and patients with CVD to develop CAD (3.7%). However, owing to the greater number of patients with CAD at baseline, this group had the largest number of patients who progressed to polyvascular disease. For the CAD group, they next developed CVD in years 1, 3, and 2 (in decreasing order of occurrence). [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] È ñíîâà âñÿ ïðîáëåìà íå â PAD êàê òàêîâîé, à â ìóëüòèñîñóäèñòîì ïîðàæåíèè. Îòäåëüíî ñòîèò îòìåòèòü, ÷òî ïîâòîðíûå ãîñïèòàëèçàöèè îêàçûâàþò âåäóùèé âêëàä â ðèñêè ïàöèåíòîâ ñ PAD è ÷åðåç 3 ãîäà: [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] Ïîýòîìó ÿ äåëàþ äëÿ ñåáÿ òàêèå âûâîäû:
Íå ìîãó íå ñîãëàñèòüñÿ ñ àâòîðàìè: Clearly improved emphasis on the diagnosis and treatment of PAD is warranted. Ñîððè çà äëèííûé ïîñò |
#81
|
|||
|
|||
Journal Club, òàê Journal Club
Áóäó îòâå÷àòü ïî ÷àñòÿì, ò.ê ïîñò ïîëó÷èëñÿ äëèííûé. Öèòàòà:
Âû ñïðàøèâàåòå: ïåðâûé âîïðîñ - äåéñòâèòåëüíî ëè íàëè÷èå PAD ãîâîðèò î õóäøåì ïðîãíîçå (ïî ñðàâíåíèþ ñ CAD)? À îòâå÷àåòå íà âîïðîñ: äåéñòâèòåëüíî ëè íàëè÷èå èçîëèðîâàííîé PAD ãîâîðèò î õóäøåì ïðîãíîçå (ïî ñðàâíåíèþ ñ CAD)? Îòíîñèòåëüíî âòîðîãî âîïðîñà ìû óæå äàâíî ñ óâàæàåìûìè êîëëåãàìè ñîøëèñü íà òîì, ÷òî "íåò" Îòíîñèòåëüíî ïåðâîãî âîïðîñà âñå òîæå ïðîñòî: ñ÷èòàåòñÿ ñìåðòíîñòü ó áîëüíûõ, ó êîòîðûõ â äèàãíîçå ñòîèò PAD è ó áîëüíûõ, ó êîòîðûõ â äèàãíîçå ñòîèò CAD. Îòâåò, êàê áû, òîæå èçâåñòåí. |
#82
|
|||
|
|||
Öèòàòà:
Åñëè äà, òî Âû íåïðàâû. Íà ãðàôèêè ïðåâåäåíî êîëè÷åñòâî ïàöèåíòîâ â êàæäîé ãðóïïå. Ïðîñòîé ðàññ÷åò: PAD Îáùåå êîëè÷åñòâî ïàöèåíòîâ ñ PAD=2485+2271+614+748=6118 Èç íèõ ñ ñîïóòñòâóþùåì ïîðàæåíèåì äðóãèõ áàññåéíîâ=2271+614+748=3633 ×àñòîòà ñîïóòñòâóþùåãî ïîðàæåíèÿ äðóãèõ áàññåéíîâ=3633*100/6118=59,4% CAD Îáùåå êîëè÷åñòâî ïàöèåíòîâ ñ CAD=21458+3997+2271+748=28474 Èç íèõ ñ ñîïóòñòâóþùåì ïîðàæåíèåì äðóãèõ áàññåéíîâ=3997+2271+748=7016 ×àñòîòà ñîïóòñòâóþùåãî ïîðàæåíèÿ äðóãèõ áàññåéíîâ=7016*100/28474=24.6% Óâàæàåìûé Gilarov íåñêîëüêèìè ñîîáùåíèÿìè Âûøå èìåííî ýòè öèôðû è ïðèâåë: |
#83
|
||||
|
||||
È âñå æå, íà ìîé âçãëÿä, ãëàâíîé ïðîáëåìîé, îïðåäåëÿþùåé ïðîãíîç, ÿâëÿåòñÿ íåàäåêâàòíîå ëå÷åíèå ó ïàöèåíòîâ ñ ÏÀÄ: òàê áûëî 10 ëåò íàçàä, òàêàÿ æå òåíäåíöèÿ è ñîõðàíÿåòñÿ ïî ñåé äåíü, âîò ôðàãìåíò äèñêóññèè èç íåìåöêîé ñòàòüè:
The finding from REACH that patients with PAD only receive secondary prevention measures less frequently than (PAD+) CAD patients, was consistent for all above mentioned drugs, but was particularly marked for statin, ACE inhibitor, beta blocker therapy and smokig cessation. Such undertreatment has been reported earlier in various settings and countries, for example in the US-American PARTNERS program in 1999 [18]. Further, three large-scale observational studies in France (ECLAT1 [5] PRISMA [7], APRES[8]) in 2004 have reported low treatment rates of patients with PAD (antiplatelets: PAD-only 79% vs. CAD-only 83%; statins: 40% vs. 62%, antihypertensive drugs: 27% vs. 38%) [6]. In getABI in 2001, the situation was similar (antiplatelets: PAD only vs. CAD ± PAD 53% vs. 65%; statins 35% vs. 57%, antihypertensive drugs: 93% vs. 96%) [30]. Other more recent investigations in UK [33], the USA [27], and France [13] indicated that the situation is improving, but still far from optimal. The reasons for the relative undertreatment of PAD patients are speculative, and manifold. On the level of the treating physicians they may be due to lack of awareness of the consequences of PAD. There are clear concepts of ‘‘cross manifestations’’ of atherosclerosis and atherothrombosis, together with the ‘‘cross risk’’ indicating that if atherosclerotic disease is diagnosed in an arterial segment, the risk of manifestations in other vascular territories is significantly elevated. However, this may not be penetrated enough [24], despite the fact that large studies such as the Framingham Study [26], the Rotterdam Study [14] or the getABI Study [12] have shown the drastically increased risk of premature mortality (doubled or tripled in PAD compared to unselected patients without PAD; even five-fold if PAD and diabetes occur concomitantly). Nonetheless many physicians seem to see the fate of PAD patients in the loss of the extremity, which is in reality only 1–2% and therefore very low compared to the risk of myocardial infarction or stroke. A survey among 1,578 general physicians and vascular specialists in the US confirmed that in PAD patients antiplatelets, statins and training were significantly less often prescribed compared to patients with CAD [23]. The LDL cholesterol threshold which triggered treatment in PAD patients ‘‘almost always’’ was 136 ± 29 mg/dl (vs. 122 ± 34 mg/dl in CAD patients) and thus way above the recommended 100 mg/ dl threshold specified by NCEP for patients with coronary equivalent. The attitude towards cardiovascular risk factors is closely related to the practical doing: cardiologists who knew the NCEP guidelines had the highest treatment rates for PAD patients [23]... (Clin Res Cardiol. 2009 Apr;98(4):249-56.)
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#84
|
||||
|
||||
Åñëè æå ñðàâíèâàòü ñìåðòíîñòü ó ïàöèåíòîâ ñ îäèíàêîâî íàçíà÷åííûì ëå÷åíèåì, òî ïðèíöèïèàëüíîé ðàçíèöû ïîõîæå íå îêàæåòñÿ...
Medication—1-year mortality association Users of antiplatelet agents (adjusted HR 0.68, 95% CI 0.60-0.77), calcium channel blockers (adjusted HR 0.84, 95% CI 0.73-0.96), or β-blockers (adjusted HR 0.72, 95% CI 0.64-0.80) exhibited lower mortality rates than nonusers. None of these associations differed between those patients with CAD who did versus who did not have a diagnosis of concomitant PAD. For example, the HR for 1-year mortality in ASA users was 0.71 (95% CI 0.54-0.94) for those patients with CAD and PAD and 0.69 (95% CI 0.60-0.78) for those patients with CAD alone. ___ Èç Lower extremity peripheral arterial disease in individuals with coronary artery disease: prognostic importance, care gaps, and impact of therapy. Am Heart J. 2008 Feb;155(2):348-55.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#85
|
||||
|
||||
Íåò, íå äîêàçàëà. Îíà äîêàçàëà, ÷òî ïðè PAD ÷àñòîòà ìíîãîñîñóäèñòûõ ïîðàæåíèé âûøå, íî ïðè ýòîì èçîëèðîâàííàÿ PAD áîëåå áëàãîïðèÿòíà, ÷åì èçîëèðîâàííàÿ CAD. Ò. å., ñìåðòíîñòü îïðåäåëÿåò íå àòåðîñêëåðîç â íîãå, à àòåðîñêëåðîç â ñåðäöå èëè ãîëîâå. Ïðè÷èíû ñìåðòè, ñâÿçàííûå íåïîñðåäñòâåííî ñ PAD (ðàçðûâû àíåâðèçì, ãàíãðåíà) âñòðå÷àþòñÿ êóäà êàê ðåæå, ÷åì èíñóëüòû è èíôàðêòû. Äðóãèìè ñëîâàìè, ñïåöèàëèñòû ëå÷àùèå PAD äîëæíû áîëåå òùàòåëüíî èñêàòü ïðîÿâëåíèÿ àòåðîñêëåðîçà â äðóãèõ ñîñóäèñòûõ áàññåéíàõ (ñåðäöå, ìîçã). Ëþáàÿ ðàáîòà èíòåðåñíà, íî íè÷åãî ðåâîëþöèîííîãî àâòîðû íå îòêðûëè, îíè ïîäòâåðäèëè èçâåñòíûå íàáëþäåíèÿ. È ñàìè, êñòàòè, íà ðåâîëþöèîííîñòü ñâîèõ äàííûõ íå ïðåòåíäóþò. Áîëåå òîãî, ãîâîðÿò î ñóùåñòâåííûõ îãðàíè÷åíèÿõ ðåãèñòðà. Âî âñÿêîì ñëó÷àå, îíè íå äàâàëè îñíîâàíèé ãîâîðèòü î òîì, ÷òî îêàçûâàåòñÿ àòåðîñêëåðîòè÷åñêàÿ áëÿøêà â îáùåé áåäðåííîé àðòåðèè îïàñíåå áëÿøêè â ñòâîëå ËÊÀ.
|
#86
|
|||
|
|||
Öèòàòà:
|
#87
|
||||
|
||||
Íàâåðíîå, åñëè äèàãíîç "PAD" äîïîëíÿòü àâòîìàòèöêè "silent CAD, CVD", òî è íàçíà÷àåìîñòü ïðåïàðàòîâ áóäåò óâåëè÷èâàòüñÿ...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#88
|
|||
|
|||
Öèòàòà:
Öèòàòà:
Ìû ãîâîðèì î ðàçíûõ âåùàõ. Íèêòî íå ñïîðèò, ÷òî ïàöèåíòû ñ PAD óìðóò ñêîðåå âñåãî íå îò PAD. Ýòî íèêàê íå âëèÿåò íà òîò ôàêò, ÷òî îíè óìðóò, è, âåðîÿòíî, äîâîëüíî ñêîðî. Çíà÷èò, íà ýòó ïîïóëÿöèþ è íàäî áðîñèòü "óäàðíûå òåðàïåâòè÷åñêèå ñèëû". Îñîáåííî, ïðèíèìàÿ âî âíèìàíèå öèòàòû îò Dr. Vad'à î òîì, ÷òî ýòè ïàöèåíòû ïîëó÷àþò íåäîñòàòî÷íóþ òåðàïèþ. |
#89
|
|||
|
|||
Äà, íî ýòî íå ðåøèò âîïðîñà ñ îäíîâðåìåííîé îïòèìèçàöèè òåðàïèè è êîíòðîëÿ ïðîãðåññèè PAD. Õèðóðãè íå ìîãóò ïåðâîå, à òåðàïåâòû âòîðîå. Ïàöèåíò ïðèäåò íà êîíòðîëü PAD, â ãîëîâå ó íåãî çàïå÷àòëèòñÿ, ÷òî ó âðà÷à áûë, à òåðàïèþ-òî åìó è íå ñêîððåêòèðîâàëè. Âîò Âàì è ïðè÷èíà ïðîáëåìû ñ "íåäîëå÷åííîñòüþ".
|
#90
|
||||
|
||||
Âñå-òàêè, ïîêà íå ìîãó ñîãëàñèòüñÿ ñ Âàøèì ïîñòóëàòîì "îïòèìèçàöèè òåðàïèè" - ðå÷ü èäåò î íàçíà÷åíèè èëè íå íàçíà÷åíèè 4-5 áàçîâûõ ïðåïàðàòîâ ó òàêèõ ïàöèåíòîâ, à íå î òîì, ÷òî íàïð. íàçíà÷åíèå 10 ìã ðàìèïðèëà îñòàíîâèò ïðîãðåññèþ PAD, åñëè íà 5 ìã òàêîâàÿ ïðîãðåññèÿ âñå åøå áóäåò îòìå÷àòüñÿ. Ñ äðóãîé ñòîðîíû, îòñóòñòâóþò äàííûå, ÷òî îñòàíîâêà ïðîãðåññèè PAD íà 2-3 ïðåïàðàòàõ äîñòàòî÷íûé ïðîãíîñòè÷åñêèé ïîñûë, ÷òî áû íå íàçíà÷èòü âñå 4-5 ëåêàðñòâ.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |